Annual report
5199.TEDINET S100W2HG
Period2024-04-01 → 2025-03-31
Filed2025-06-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 146
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥7.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥7.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥8.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥209m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥440m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥171m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥382m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥730m | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥486m | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥227m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥383m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥376m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥298m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥290m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥517m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥143m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥170m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥298m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥290m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥11.1bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥11.3bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥11.5bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥11.8bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥12.4bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.0bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥7.5bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.1bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.9bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.6bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥3.3bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.3bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.0bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.4bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥634m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥211m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥772m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥706m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥278m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥123m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥76m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥152m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥111m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥282m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥347m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥676m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥803m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥450m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥235.19 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥228.42 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥407.89 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-112.56 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥134.03 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,209.1 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,042.65 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,820.6 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,442.65 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,604.82 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 36.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.2% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.2% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.6% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.5% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.5% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.3% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 250 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 278 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 276 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 287 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 285 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥7.1bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥7.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥8.0bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥8.1bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥6.7bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥204m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥426m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥167m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥370m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥714m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥496m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥213m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥379m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥363m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥297m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥283m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥504m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥167m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥160m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥10.9bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥11.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥11.4bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥11.7bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥12.4bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥7.0bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥7.5bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.9bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.5bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥3.0bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥3.3bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.5bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥234.59 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥223.35 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥397.23 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-131.92 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥125.82 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥78 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,091.45 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,964.09 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,760.74 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,388.09 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,575.31 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 35.8% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.8% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.8% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.3% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.7% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.4% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,286,199 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,286,199 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,286,199 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,286,199 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,286,199 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 245 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 272 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 272 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 281 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 279 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 60
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥6m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥16m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥3.3bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥455m |
| Medical Equipmentreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥43m |
| Medical Equipmentreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥104m |
| Medical Equipmentreportable segment | employees | at 2025-03-31 | 87 pure |
| Medical Equipmentreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.5bn |
| Medical Equipmentreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.5bn |
| Medical Equipmentreportable segment | segment assets | at 2025-03-31 | ¥3.5bn |
| Medical Equipmentreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥8m |
| Precision Equipmentreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥77m |
| Precision Equipmentreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥141m |
| Precision Equipmentreportable segment | employees | at 2025-03-31 | 121 pure |
| Precision Equipmentreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥4.1bn |
| Precision Equipmentreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.1bn |
| Precision Equipmentreportable segment | segment assets | at 2025-03-31 | ¥3.6bn |
| Precision Equipmentreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥710m |
| SP Divisionreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥24,000 |
| SP Divisionreportable segment | employees | at 2025-03-31 | 1 pure |
| SP Divisionreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥390m |
| SP Divisionreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥390m |
| SP Divisionreportable segment | segment assets | at 2025-03-31 | ¥84m |
| SP Divisionreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥23m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥217m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥271m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥7.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥7.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥7.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥664m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥21m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥23m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥2.8bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥467m |
| Medical Equipmentreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥24m |
| Medical Equipmentreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥111m |
| Medical Equipmentreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Medical Equipmentreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Medical Equipmentreportable segment | segment assets | at 2024-03-31 | ¥3.8bn |
| Medical Equipmentreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥9m |
| Precision Equipmentreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥65m |
| Precision Equipmentreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥159m |
| Precision Equipmentreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥4.2bn |
| Precision Equipmentreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥4.2bn |
| Precision Equipmentreportable segment | segment assets | at 2024-03-31 | ¥4.1bn |
| Precision Equipmentreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥831m |
| SP Divisionreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥33,000 |
| SP Divisionreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥735m |
| SP Divisionreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥735m |
| SP Divisionreportable segment | segment assets | at 2024-03-31 | ¥230m |
| SP Divisionreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥36m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥90m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥290m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥7.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥7.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥8.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥906m |
| Medical Equipmentreportable segment | employees | at 2025-03-31 | 86 pure |
| Precision Equipmentreportable segment | employees | at 2025-03-31 | 117 pure |
| SP Divisionreportable segment | employees | at 2025-03-31 | 1 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,640
| Item | Context | Value | Unit |
|---|---|---|---|
| Welfare expenses sga | Prior1YearDuration | 99039000 | JPY |
| Welfare expenses sga | CurrentYearDuration | 103193000 | JPY |
| Freightage expenses sga | Prior1YearDuration | 144765000 | JPY |
| Freightage expenses sga | CurrentYearDuration | 115035000 | JPY |
| Advertising expenses sga | Prior1YearDuration | 3383000 | JPY |
| Advertising expenses sga | CurrentYearDuration | 2419000 | JPY |
| Promotion expenses sga | Prior1YearDuration | 37920000 | JPY |
| Promotion expenses sga | CurrentYearDuration | 35537000 | JPY |
| Depreciation sga | Prior1YearDuration | 27179000 | JPY |
| Depreciation sga | CurrentYearDuration | 23088000 | JPY |
| Commission fee sga | Prior1YearDuration | 158398000 | JPY |
| Commission fee sga | CurrentYearDuration | 136380000 | JPY |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period | Prior1YearDuration | 194677000 | JPY |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period | CurrentYearDuration | 172824000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E01109-000MedicalEquipmentReportableSegmentsMember | 2367054000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E01109-000PrecisionEquipmentReportableSegmentsMember | 4168915000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E01109-000SPDivisionReportableSegmentMember | 735208000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E01109-000FoodContainerMember | 236937000 | JPY |
| Revenues from external customers | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 7508117000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | - | JPY |
| Revenues from external customers | Prior1YearDuration | 7508117000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E01109-000MedicalEquipmentReportableSegmentsMember | - | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E01109-000PrecisionEquipmentReportableSegmentsMember | - | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E01109-000SPDivisionReportableSegmentMember | - | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E01109-000FoodContainerMember | - | JPY |
| Transactions with other segments | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | - | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | - | JPY |
| Transactions with other segments | Prior1YearDuration | - | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E01109-000MedicalEquipmentReportableSegmentsMember | 2367054000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E01109-000PrecisionEquipmentReportableSegmentsMember | 4168915000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E01109-000SPDivisionReportableSegmentMember | 735208000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E01109-000FoodContainerMember | 236937000 | JPY |
| Net sales | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 7508117000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | - | JPY |
| Net sales | Prior1YearDuration | 7508117000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E01109-000MedicalEquipmentReportableSegmentsMember | 8892000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E01109-000PrecisionEquipmentReportableSegmentsMember | 831259000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E01109-000SPDivisionReportableSegmentMember | 36285000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E01109-000FoodContainerMember | 29870000 | JPY |
| Operating income | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 906308000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | -466577000 | JPY |
| Operating income | Prior1YearDuration | 439731000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E01109-000MedicalEquipmentReportableSegmentsMember | 3817532000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E01109-000PrecisionEquipmentReportableSegmentsMember | 4120729000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E01109-000SPDivisionReportableSegmentMember | 230309000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E01109-000FoodContainerMember | 394160000 | JPY |
| Assets | Prior1YearInstant_TotalOfReportableSegmentsAndOthersMember | 8562732000 | JPY |
| Assets | Prior1YearInstant_ReconcilingItemsMember | 2763882000 | JPY |
| Assets | Prior1YearInstant | 11326615000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E01109-000MedicalEquipmentReportableSegmentsMember | 111224000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |